A Canadian Adult Spinal Muscular Atrophy Outcome Measures Toolkit: Results of a National Consensus using a Modified Delphi Method

Jeremy Slayter; Victoria Hodgkinson; Josh Lounsberry; Bernard Brais; Kristine Chapman; Angela Genge; Aaron Izenberg; Wendy Johnston; Hanns Lochmüller; Erin O'Ferrall; Gerald Pfeffer; Stephanie Plamondon; Xavier Rodrigue; Kerri Schellenberg; Christen Shoesmith; Christine Stables; Monique Taillon; Jodi Warman-Chardon; Lawrence Korngut; Colleen O'Connell

doi:10.3233/JND-200617

A Canadian Adult Spinal Muscular Atrophy Outcome Measures Toolkit: Results of a National Consensus using a Modified Delphi Method

Jeremy Slayter, Victoria Hodgkinson, Josh Lounsberry, Bernard Brais, Kristine Chapman, Angela Genge, Aaron Izenberg, Wendy Johnston, Hanns Lochmüller, Erin O'Ferrall, Gerald Pfeffer, Stephanie Plamondon, Xavier Rodrigue, Kerri Schellenberg, Christen Shoesmith, Christine Stables, Monique Taillon, Jodi Warman-Chardon, Lawrence Korngut, Colleen O'Connell

Medicine

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

Background: Spinal Muscular Atrophy (SMA) is a rare disease that affects 1 in 11 000 live births. Recent developments in SMA treatments have included new disease-modifying therapies that require high quality data to inform decisions around initiation and continuation of therapy. In Canada, there are no nationally agreed upon outcome measures (OM) used in adult SMA. Standardization of OM is essential to obtain high quality data that is comparable among neuromuscular clinics. Objective: To develop a recommended toolkit and timing of OM for assessment of adults with SMA. Methods: A modified delphi method consisting of 2 virtual voting rounds followed by a virtual conference was utilized with a panel of expert clinicians treating adult SMA across Canada. Results: A consensus-derived toolkit of 8 OM was developed across three domains of function, with an additional 3 optional measures. Optimal assessment frequency is 12 months for most patients regardless of therapeutic access, while patients in their first year of receiving disease-modifying therapy should be assessed more frequently. Conclusions: The implementation of the consensus-derived OM toolkit will improve monitoring and assessment of adult SMA patients, and enrich the quality of real-world evidence. Regular updates to the toolkit must be considered as new evidence becomes available.

Original language	English
Pages (from-to)	579-588
Number of pages	10
Journal	Journal of Neuromuscular Diseases
Volume	8
Issue number	4
DOIs	https://doi.org/10.3233/JND-200617
Publication status	Published - 2021

Bibliographical note

Funding Information:
Victoria Hodgkinson reports personal fees from Biogen and Hoffman-La Roche. Bernard Brais contributes to teaching sessions organized by Biogen, and participates in medical consultant meetings with Biogen and Hoffman-La Roche. Kristine Chapman serves on the Expensive Drugs for Rare Diseases Working Group. Angela Genge reports grants from Biogen; and consulting fees from AL-S Pharma, Alexion, Quralis, Cytokinetics, Mitsubishi-Tanabe, and Hoffman-La Roche. Aaron Izenberg reports personal fees Biogen, Mitsubishi-Tanabe, Hoffman-La Roche, Takeda, Akcea, Alnylam, Genzyme. Wendy Johnston reports personal fees from Biogen and Mitsubishi-Tanabe. Erin O’Farrell reports personal fees from Biogen, and grants from Sanofi Genzyme, Acceleron, and Grifols. Xavier Rodrigue reports personal fees from Hoffman-La Roche and Biogen. Christen Shoesmith serves on advisory boards for Mitsubishi-Tanabe and Orion Pharmaceuticals and is also a primary investigator for a clinical trial sponsored by Cytokinetics; a family member is employed by Hoffman-La Roche. Monique Taillon reports serving on Advisory Boards for Biogen, Hoffman-La Roche and Novartis. Lawrence Korngut reports grants and personal fees from Biogen and Hoffman-La Roche; and personal fees from Novartis. Colleen O’Connell reports grants from the New Brunswick Health Research Foundation (NBHRF) and personal fees from Hoffman-La Roche.

Funding Information:
The authors would like to thank the Dalhousie University Faculty of Medicine, and the New Brunswick Health Research Foundation (NBHRF) for funding support. The authors would also like to thank the CNDR for their assistance in facilitating this work.

Publisher Copyright:
© 2021 - The authors. Published by IOS Press.

ASJC Scopus Subject Areas

Neurology
Clinical Neurology

PubMed: MeSH publication types

Journal Article

Access to Document

10.3233/JND-200617

Cite this

Slayter, J., Hodgkinson, V., Lounsberry, J., Brais, B., Chapman, K., Genge, A., Izenberg, A., Johnston, W., Lochmüller, H., O'Ferrall, E., Pfeffer, G., Plamondon, S., Rodrigue, X., Schellenberg, K., Shoesmith, C., Stables, C., Taillon, M., Warman-Chardon, J., Korngut, L., & O'Connell, C. (2021). A Canadian Adult Spinal Muscular Atrophy Outcome Measures Toolkit: Results of a National Consensus using a Modified Delphi Method. Journal of Neuromuscular Diseases, 8(4), 579-588. https://doi.org/10.3233/JND-200617

Slayter, J, Hodgkinson, V, Lounsberry, J, Brais, B, Chapman, K, Genge, A, Izenberg, A, Johnston, W, Lochmüller, H, O'Ferrall, E, Pfeffer, G, Plamondon, S, Rodrigue, X, Schellenberg, K, Shoesmith, C, Stables, C, Taillon, M, Warman-Chardon, J, Korngut, L & O'Connell, C 2021, 'A Canadian Adult Spinal Muscular Atrophy Outcome Measures Toolkit: Results of a National Consensus using a Modified Delphi Method', Journal of Neuromuscular Diseases, vol. 8, no. 4, pp. 579-588. https://doi.org/10.3233/JND-200617

@article{e0d855eb82a943b4bc24b3774ed80947,

title = "A Canadian Adult Spinal Muscular Atrophy Outcome Measures Toolkit: Results of a National Consensus using a Modified Delphi Method",

abstract = "Background: Spinal Muscular Atrophy (SMA) is a rare disease that affects 1 in 11 000 live births. Recent developments in SMA treatments have included new disease-modifying therapies that require high quality data to inform decisions around initiation and continuation of therapy. In Canada, there are no nationally agreed upon outcome measures (OM) used in adult SMA. Standardization of OM is essential to obtain high quality data that is comparable among neuromuscular clinics. Objective: To develop a recommended toolkit and timing of OM for assessment of adults with SMA. Methods: A modified delphi method consisting of 2 virtual voting rounds followed by a virtual conference was utilized with a panel of expert clinicians treating adult SMA across Canada. Results: A consensus-derived toolkit of 8 OM was developed across three domains of function, with an additional 3 optional measures. Optimal assessment frequency is 12 months for most patients regardless of therapeutic access, while patients in their first year of receiving disease-modifying therapy should be assessed more frequently. Conclusions: The implementation of the consensus-derived OM toolkit will improve monitoring and assessment of adult SMA patients, and enrich the quality of real-world evidence. Regular updates to the toolkit must be considered as new evidence becomes available.",

author = "Jeremy Slayter and Victoria Hodgkinson and Josh Lounsberry and Bernard Brais and Kristine Chapman and Angela Genge and Aaron Izenberg and Wendy Johnston and Hanns Lochm{\"u}ller and Erin O'Ferrall and Gerald Pfeffer and Stephanie Plamondon and Xavier Rodrigue and Kerri Schellenberg and Christen Shoesmith and Christine Stables and Monique Taillon and Jodi Warman-Chardon and Lawrence Korngut and Colleen O'Connell",

note = "Funding Information: Victoria Hodgkinson reports personal fees from Biogen and Hoffman-La Roche. Bernard Brais contributes to teaching sessions organized by Biogen, and participates in medical consultant meetings with Biogen and Hoffman-La Roche. Kristine Chapman serves on the Expensive Drugs for Rare Diseases Working Group. Angela Genge reports grants from Biogen; and consulting fees from AL-S Pharma, Alexion, Quralis, Cytokinetics, Mitsubishi-Tanabe, and Hoffman-La Roche. Aaron Izenberg reports personal fees Biogen, Mitsubishi-Tanabe, Hoffman-La Roche, Takeda, Akcea, Alnylam, Genzyme. Wendy Johnston reports personal fees from Biogen and Mitsubishi-Tanabe. Erin O{\textquoteright}Farrell reports personal fees from Biogen, and grants from Sanofi Genzyme, Acceleron, and Grifols. Xavier Rodrigue reports personal fees from Hoffman-La Roche and Biogen. Christen Shoesmith serves on advisory boards for Mitsubishi-Tanabe and Orion Pharmaceuticals and is also a primary investigator for a clinical trial sponsored by Cytokinetics; a family member is employed by Hoffman-La Roche. Monique Taillon reports serving on Advisory Boards for Biogen, Hoffman-La Roche and Novartis. Lawrence Korngut reports grants and personal fees from Biogen and Hoffman-La Roche; and personal fees from Novartis. Colleen O{\textquoteright}Connell reports grants from the New Brunswick Health Research Foundation (NBHRF) and personal fees from Hoffman-La Roche. Funding Information: The authors would like to thank the Dalhousie University Faculty of Medicine, and the New Brunswick Health Research Foundation (NBHRF) for funding support. The authors would also like to thank the CNDR for their assistance in facilitating this work. Publisher Copyright: {\textcopyright} 2021 - The authors. Published by IOS Press.",

year = "2021",

doi = "10.3233/JND-200617",

language = "English",

volume = "8",

pages = "579--588",

journal = "Journal of Neuromuscular Diseases",

issn = "2214-3599",

publisher = "IOS Press BV",

number = "4",

}

TY - JOUR

T1 - A Canadian Adult Spinal Muscular Atrophy Outcome Measures Toolkit

T2 - Results of a National Consensus using a Modified Delphi Method

AU - Slayter, Jeremy

AU - Hodgkinson, Victoria

AU - Lounsberry, Josh

AU - Brais, Bernard

AU - Chapman, Kristine

AU - Genge, Angela

AU - Izenberg, Aaron

AU - Johnston, Wendy

AU - Lochmüller, Hanns

AU - O'Ferrall, Erin

AU - Pfeffer, Gerald

AU - Plamondon, Stephanie

AU - Rodrigue, Xavier

AU - Schellenberg, Kerri

AU - Shoesmith, Christen

AU - Stables, Christine

AU - Taillon, Monique

AU - Warman-Chardon, Jodi

AU - Korngut, Lawrence

AU - O'Connell, Colleen

N1 - Funding Information: Victoria Hodgkinson reports personal fees from Biogen and Hoffman-La Roche. Bernard Brais contributes to teaching sessions organized by Biogen, and participates in medical consultant meetings with Biogen and Hoffman-La Roche. Kristine Chapman serves on the Expensive Drugs for Rare Diseases Working Group. Angela Genge reports grants from Biogen; and consulting fees from AL-S Pharma, Alexion, Quralis, Cytokinetics, Mitsubishi-Tanabe, and Hoffman-La Roche. Aaron Izenberg reports personal fees Biogen, Mitsubishi-Tanabe, Hoffman-La Roche, Takeda, Akcea, Alnylam, Genzyme. Wendy Johnston reports personal fees from Biogen and Mitsubishi-Tanabe. Erin O’Farrell reports personal fees from Biogen, and grants from Sanofi Genzyme, Acceleron, and Grifols. Xavier Rodrigue reports personal fees from Hoffman-La Roche and Biogen. Christen Shoesmith serves on advisory boards for Mitsubishi-Tanabe and Orion Pharmaceuticals and is also a primary investigator for a clinical trial sponsored by Cytokinetics; a family member is employed by Hoffman-La Roche. Monique Taillon reports serving on Advisory Boards for Biogen, Hoffman-La Roche and Novartis. Lawrence Korngut reports grants and personal fees from Biogen and Hoffman-La Roche; and personal fees from Novartis. Colleen O’Connell reports grants from the New Brunswick Health Research Foundation (NBHRF) and personal fees from Hoffman-La Roche. Funding Information: The authors would like to thank the Dalhousie University Faculty of Medicine, and the New Brunswick Health Research Foundation (NBHRF) for funding support. The authors would also like to thank the CNDR for their assistance in facilitating this work. Publisher Copyright: © 2021 - The authors. Published by IOS Press.

PY - 2021

Y1 - 2021

N2 - Background: Spinal Muscular Atrophy (SMA) is a rare disease that affects 1 in 11 000 live births. Recent developments in SMA treatments have included new disease-modifying therapies that require high quality data to inform decisions around initiation and continuation of therapy. In Canada, there are no nationally agreed upon outcome measures (OM) used in adult SMA. Standardization of OM is essential to obtain high quality data that is comparable among neuromuscular clinics. Objective: To develop a recommended toolkit and timing of OM for assessment of adults with SMA. Methods: A modified delphi method consisting of 2 virtual voting rounds followed by a virtual conference was utilized with a panel of expert clinicians treating adult SMA across Canada. Results: A consensus-derived toolkit of 8 OM was developed across three domains of function, with an additional 3 optional measures. Optimal assessment frequency is 12 months for most patients regardless of therapeutic access, while patients in their first year of receiving disease-modifying therapy should be assessed more frequently. Conclusions: The implementation of the consensus-derived OM toolkit will improve monitoring and assessment of adult SMA patients, and enrich the quality of real-world evidence. Regular updates to the toolkit must be considered as new evidence becomes available.

AB - Background: Spinal Muscular Atrophy (SMA) is a rare disease that affects 1 in 11 000 live births. Recent developments in SMA treatments have included new disease-modifying therapies that require high quality data to inform decisions around initiation and continuation of therapy. In Canada, there are no nationally agreed upon outcome measures (OM) used in adult SMA. Standardization of OM is essential to obtain high quality data that is comparable among neuromuscular clinics. Objective: To develop a recommended toolkit and timing of OM for assessment of adults with SMA. Methods: A modified delphi method consisting of 2 virtual voting rounds followed by a virtual conference was utilized with a panel of expert clinicians treating adult SMA across Canada. Results: A consensus-derived toolkit of 8 OM was developed across three domains of function, with an additional 3 optional measures. Optimal assessment frequency is 12 months for most patients regardless of therapeutic access, while patients in their first year of receiving disease-modifying therapy should be assessed more frequently. Conclusions: The implementation of the consensus-derived OM toolkit will improve monitoring and assessment of adult SMA patients, and enrich the quality of real-world evidence. Regular updates to the toolkit must be considered as new evidence becomes available.

UR - http://www.scopus.com/inward/record.url?scp=85112029465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85112029465&partnerID=8YFLogxK

U2 - 10.3233/JND-200617

DO - 10.3233/JND-200617

M3 - Article

C2 - 33867362

AN - SCOPUS:85112029465

SN - 2214-3599

VL - 8

SP - 579

EP - 588

JO - Journal of Neuromuscular Diseases

JF - Journal of Neuromuscular Diseases

IS - 4

ER -

A Canadian Adult Spinal Muscular Atrophy Outcome Measures Toolkit: Results of a National Consensus using a Modified Delphi Method

Abstract

Bibliographical note

ASJC Scopus Subject Areas

PubMed: MeSH publication types

Access to Document

Other files and links

Fingerprint

Cite this